Loading
A phase 1 trial of RGT-61159 run by Rgenta Therapeutics Inc, active and no longer recruiting.
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) is a phase 1 interventional study registered as NCT06462183 by Rgenta Therapeutics Inc, with 105 participants planned, started 2024-08-19. Conditions recorded: Adenoid Cystic Carcinoma and Colorectal Cancer. Interventions recorded: RGT-61159 and lenvatinib.
Shares Salivary gland cancers and the tag pipeline.
Shares Salivary gland cancers and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Salivary gland cancers and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/